ANTIGEN LB39-AA Uses, Dosage, Side Effects and more
ANTIGEN LB39-AA is under investigation in clinical trial NCT01748747 (Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery).
| Trade Name | ANTIGEN LB39-AA |
| Generic | Melanoma antigen recognized by T-cells 1 |
| Melanoma antigen recognized by T-cells 1 Other Names | ANTIGEN LB39-AA, ANTIGEN SK29-AA, MART1 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
